A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis.

A total of 45 non-uremic dogs, with clinical signs indicating leishmaniosis, entered the study. Diagnosis was confirmed by indirect immunofluorescence assay (IFA) on serum and polymerase chain reaction (PCR) on bone marrow samples. The dogs were randomly allocated into Group A (n=37) that received allopurinol (10mg/kg B.W., per os, twice daily) for 4 consecutive months, and Group B (n=8) that were placebo-treated. Clinical signs were scored just before and at monthly intervals throughout the study period, in a blinded and independent fashion. Complete blood count, serum biochemistry profile, urinalysis, lymph node and bone marrow parasitology, IFA and enzyme-linked immunosorbent assay (ELISA) serology and bone marrow PCR were carried out at the beginning and at the end of the trial. A total of three Group A and one Group B dogs died of end stage kidney disease that developed during the trial. In Group A animals that endured the trial there was a significant improvement in the general body condition, conjunctivitis, peripheral lymphadenopathy, splenomegaly, masticatory muscle atrophy, ulcerative stomatitis, epistaxis, exfoliative dermatitis, cutaneous ulcerations, blepharitis and nasodigital hyperkeratosis. The same observation was made for anemia, lymphopenia, hyperproteinemia, hyperglobulinemia, hyperphosphatemia, increased alkaline phosphatase activity and the low albumin/globulin ratio. By contrast, no improvement of any kind was seen in Group B dogs. Lymph node and bone marrow parasite numbers were significantly decreased in Group A animals. In Group B, that occurred only in the lymph nodes. Apart from remission of clinical signs and restoration to normal of clinicopathological abnormalities, allopurinol did not eliminate Leishmania organisms, as the PCR result on bone marrow was still positive in all the dogs that finished the trial.     

Progress toward molecular characterization of ectoparasite modulation of host immunity.

Ectoparasitic arthropods and vector-borne infectious agents are global medical and veterinary public health concerns. Economic impact due to direct effects of infestation and disease transmission are significant. These problems are increased by development of arthropod resistance to insecticides/acaricides; drug resistance of vector-borne pathogens; and, lack of effective vaccines to prevent many of these diseases. There is much to be gained from understanding the complex array of immunological interactions occurring at the arthropod-host-pathogen interface. One application of that knowledge is the development of novel vaccines for the control of both ectoparasitic arthropods and the diseases they transmit. We now realize that blood-feeding arthropods are not simply flying or crawling hypodermic needles and syringes. Ectoparasitic arthropods are not passive partners in their relationships with the immune systems of their hosts. These clever invertebrates produce numerous pharmacologically active molecules that help them migrate through tissues of their hosts or to successfully obtain blood meals. Arthropod parasites stimulate a spectrum of host immune responses that could potentially impair development, reduce feeding success, or kill the ectoparasite. Not unexpectedly, arthropods have developed sophisticated arsenals of countermeasures that modulate or deviate host immune responses. Not only does arthropod modulation of host immunity facilitate survival in tissues or increase the likelihood of obtaining a blood meal, but it is increasingly recognized as a critical factor in pathogen transmission. Those countermeasures to host immune defenses are the topics of this review. Emphasis is placed on our current understanding of the molecular bases of those changes; the molecules responsible for host immunomodulation; contemporary approaches for studying these complex relationships; and, the potential for using this information to develop innovative vaccine-based control strategies.     

Ovarian hemangioma in swine

Eighteen (3.9%) ovarian hemangiomas were diagnosed in a survey of reproductive disorders in 460 sows from two to eight years of age during a three-year study. Ovarian hemangiomas only were observed in sows aged over 30 months, and no such neoplasms were found in 42 gilts. The incidence of ovarian hemangioma was highest at five to eight years of age. Of the 18 sows with ovarian hemangioma, one was purebred and 17 were crossbred pigs; of these, twelve had farrowed 12 to 15 litters, four had farrowed six to 11 litters and two had farrowed three litters. All 18 sows with ovarian hemangioma had one or more clinical signs related to reproductive disorders including small litter size, agalactia, fertilization failure, fetal death, silent estrus, anestrus, abortion, and stillbirth. The pathological features of the neoplasms in sows were similar to those described previously in swine and in man. Spontaneous ovarian hemangioma might provide a model for investigation of the etiology and pathogenesis of ovarian hemangioma in man.     

Anthelmintic treatment of pastured dairy cattle in California

The relationship of anthelmintic treatment for subclinical gastrointestinal nematode parasitism with resultant milk production was studied on 3 California dairies where animals were maintained on a pasture-based nutritional program. All of the animals that started lactating (freshened) during a 12-month period participated in trials in which coumaphos was given as a feed top dressing to animals averaging 30 days into lactation. All of the animals that freshened during the subsequent 12-month period from 2 of the same 3 dairies participated in trials in which thiabendazole was administered at or within 2 weeks before freshening. Anthelmintic administration during 2 consecutive lactation cycles under the conditions of the present study resulted in no consistent reproducible significant changes in milk production.     

Epidemiology of teat lesions in a dairy herd. II. Associations with subclinical mastitis

Even small teat lesions are significantly associated with subclinical mastitis and the risk of mastitis increases as the lesions approach the teat canal. Analyses show that at least 7% of cases of subclinic mastitis would have been avoided if no teat lesions had occurred in the herd in question. Analyses also indicate that the risk of mastitis in a quarter increases by about 50% across a 10 months follow-up period (equivalent to one lactation period) after the teat has been injured.     

Restriction endonuclease patterns of bovine herpesvirus type 1 isolated from bovine mammary glands

Restriction endonuclease analysis was used, in conjunction with viral neutralization and growth-curve experiments, to compare a bovine herpesvirus type 1 (BHV-1) isolate, originally obtained from bovine mammary gland lesions, with a standard BHV-1 strain, infectious bovine rhinotracheitis virus. Although differences were not detected by viral neutralization or growth-curve experiments, restriction fragment patterns generated by Bam HI, Eco RI, Hind III, and Hpa I, revealed definite differences between the isolate and the prototype strain. Additionally, Eco RI, Hind III, and Hpa I patterns revealed that the mammary gland isolate had DNA-fragment patterns characteristic of infectious pustular vulvovaginitis strain of BHV-1, type 2b. Seemingly, type-2b isolates, similar to types 1 and 2a, may be capable of causing divergent types of infection of variable severity in cattle.